Azenta expands gene synthesis with Elegen licensing and SynPlexity acquisition

Azenta disclosed two simultaneous moves to broaden its gene‑synthesis portfolio: an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc.¹ Both actions are intended to reinforce the capabilities of the company’s GENEWIZ brand.¹ The licensing deal brings a cell‑free DNA synthesis platform into Azenta’s suite of tools.¹ The purchase adds a high‑throughput pooled gene‑assembly technology to the same portfolio.¹ The two additions address different parts of gene synthesis: Elegen contributes a platform focused on DNA quality, delivery speed and manufacturing scale, while SynPlexity adds a way to assemble many gene variants in a library.¹ That distinction matters to researchers because the announced capabilities include both preparing DNA for downstream work and producing large sets of candidates to build and test.¹ Azenta’s announcements describe a licensing agreement for Elegen’s platform and an acquisition of SynPlexity, rather than two arrangements of the same type.¹

The Elegen platform is described as a cell‑free system that improves DNA quality, speeds delivery, and scales manufacturing for GENEWIZ.¹ It also supplies sequence‑verified DNA constructs and templates, simplifying preparation for downstream experiments such as antibody discovery.¹ These attributes aim to make the synthesis process more reliable for customers.¹ The platform’s design supports rapid response to market needs.¹ Sequence verification is relevant because the platform is designed to provide constructs and templates before researchers move on to experiments such as antibody discovery.¹ The stated improvements span three practical dimensions—quality, delivery speed and manufacturing scalability—rather than describing only a change to the DNA production method.¹ For GENEWIZ customers, the intended connection is that better-quality DNA delivered faster can support downstream work, while scalable manufacturing can support the service as demand changes.¹

Elegen’s compact production workflows allow Azenta to add regional capacity close to customers as demand fluctuates.¹ Proximity of production sites is intended to reduce turnaround times for orders.¹ This approach aligns with the company’s goal of scaling services without sacrificing speed.¹ The added capacity is counted by the number of additional regional sites that can be activated on short notice.¹ The announcement presents regional production as a flexible response: capacity can be placed near customers when needed, rather than treating production scale as fixed.¹ This could matter to customers whose demand varies, because the stated purpose of the compact workflows is to add capacity as demand calls for it.¹ The fact describes an ability to add regional capacity close to customers; it does not give a count of sites or a specific activation schedule.¹

SynPlexity contributes a pooled gene‑assembly technology that can generate thousands of full‑length gene variants within a single library.¹ The technology enables the creation of large, multiplexed libraries for functional screening.¹ By delivering many variants at once, the platform reduces the time and cost of library construction.¹ These capabilities are measured by the number of distinct gene variants produced per library batch.¹ The figure described is thousands of variants in one library, indicating that the offering brings many full‑length options together in a pooled format.¹ That contrasts with considering each candidate separately: SynPlexity’s stated value is assembling a large set in a single library for researchers’ discovery work.¹ Functional screening is among the uses named for these large multiplexed libraries, alongside drug discovery and therapeutics.¹

Researchers can use SynPlexity’s system to efficiently build and test extensive candidate sets, including designs generated by artificial intelligence.¹ The high‑throughput nature of the technology supports rapid iteration in drug discovery and therapeutic development.¹ The ability to evaluate many candidates simultaneously accelerates the identification of promising leads.¹ Performance metrics focus on the volume of candidates screened per experiment.¹ Including AI-generated designs means the system is described as useful for candidate sets created by researchers as well as those produced through AI design.¹ The relevant benefit is the ability to build and test large numbers of candidates efficiently, not a claim that any one candidate will succeed.¹ Drug discovery and therapeutics are among the application areas for SynPlexity’s libraries, connecting the high-throughput approach to work that evaluates potential candidates.¹

Trey Martin, President of Multiomics at Azenta, said the investments strengthen GENEWIZ’s competitive position and accelerate growth.¹ His comment underscores the strategic intent behind the licensing and acquisition moves.¹ The statement was released through a PR Newswire announcement.¹ Martin’s perspective reflects senior leadership’s view of the expected market impact.¹ Martin’s remark characterizes the moves as investments in GENEWIZ’s position and growth, but the cited statement does not provide a quantified estimate of either outcome.¹ The comment therefore explains the company’s stated rationale, while the concrete additions described elsewhere are the Elegen platform and SynPlexity’s pooled assembly technology.¹ For customers and researchers, the strategic ambition is tied to the expanded capabilities Azenta says the two moves bring to GENEWIZ.¹

Azenta indicated that further details about the investments will be shared during its fourth‑quarter fiscal 2026 earnings call.¹ The upcoming call will provide additional quantitative information and operational plans.¹ Stakeholders are invited to listen for specifics on rollout timelines and financial expectations.¹ The timing of the disclosure aligns with the company’s regular reporting schedule.¹ The earnings call is the stated venue for more information, so the current announcement leaves some details for that later update.¹ Investors and other stakeholders seeking additional details about the investments will have to look to the fourth-quarter fiscal 2026 call, according to Azenta.¹ The cited information identifies when Azenta plans to provide further details, but does not itself specify those details.¹

Founded in New Jersey in 1999, Azenta has built a global sequencing and gene‑synthesis business under the GENEWIZ brand.¹ The company’s headquarters are now in Burlington, Massachusetts, with operations spanning North America, Europe, and Asia.¹ Its worldwide footprint supports a broad customer base across multiple continents.¹ The historical growth of the firm provides a foundation for the new technology integrations.¹ The company’s origins and current headquarters are in different states: it was founded in New Jersey and is now headquartered in Massachusetts.¹ Its operations in North America, Europe and Asia give the business a presence across those regions, while the announced Elegen workflows are intended to support regional capacity near customers.¹ That existing geographic reach is part of the context for adding technologies to the GENEWIZ business, which Azenta has developed in sequencing and gene synthesis.¹

Elegen’s proprietary cell‑free technologies are capable of building longer, higher‑quality DNA on a faster timeline for sectors such as agriculture, chemicals, healthcare, and pharma.¹ SynPlexity’s offerings focus on large, multiplexed libraries used in functional screening, drug discovery, therapeutics, and related applications.¹ Together, the two platforms expand the range of services GENEWIZ can provide to its diverse client base.¹ The combined capabilities are quantified by the increased volume of DNA constructs and library variants that can be delivered to customers.¹ Elegen’s stated industry reach includes agricultural and chemical work as well as healthcare and pharma, while SynPlexity’s applications include screening, drug discovery and therapeutics.¹ The platforms therefore serve different but related needs: one builds longer, higher-quality DNA faster, and the other supplies large libraries for functional evaluation.¹ Researchers in the fields named for either offering are the prospective users described in the announcement, though the facts do not specify customer numbers or adoption levels.¹